

**Drugs and Therapeutics (D & T) Committee
Meeting Results
October 21, 2021**

Drug Name	Review Type	Committee Recommendation	Preferred Status – Final Determination
Qelbree	New Drug Initial Review	Non-Preferred	Non-Preferred
Verquvo	New Drug Initial Review	Preferred	Preferred with PA
Rybelsus	New Drug Review*	Preferred	Preferred with PA

**Growth Hormones
Class Review Results**

Humatrope			Non-Preferred
Genotropin		Preferred with PA	
Norditropin			Non-Preferred
Omnitrope			Non-Preferred
Saizen			Non-Preferred
Zorbtive			Non-Preferred
Nutropin			Non-Preferred
Zomactin			Non-Preferred

**Multiple-Sclerosis-Orals
Class Review Results**

Ampyra			Non-Preferred
Dalfampridin			Non-Preferred
Aubagio			Non-Preferred
Bafiertam			Non-Preferred
Gilenya		Preferred with PA	
Mavenclad			Non-Preferred
Mayzent			Non-Preferred
Ponvory			Non-Preferred
Tecfidera	Preferred		
Dimethylfumarate			Non-Preferred
Vumerity			Non-Preferred
Zeposia			Non-Preferred

**Multiple Sclerosis-Injectables
Class Review Results**

Extavia			Non-Preferred
Kesimpta			Non-Preferred
Glatiramer 20mg			Non-Preferred
Glatiramer 40mg			Non-Preferred
Glatopa 20mg			Non-Preferred
Glatopa 40mg			Non-Preferred
Copaxone 20mg	Preferred		
Copaxone 40mg	Preferred		
Rebif	Preferred		
Ocrevus			Non-Preferred
Betaseron	Preferred		
Lemtrada			Non-Preferred
Avonex			Non-Preferred
Tysabri			Non-Preferred
Plegridy			Non-Preferred